Board summary
Key figures
46,051
Registered population
62.6% aged 18–64
13.2%
Aged 65+
ICB 14.9% · England 17.9%
34.1%
Ethnic minority (non-White)
8.8% Asian · England 9.6%
77.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~33,106
Core20 residents (est.)
Resident basis; registered basis ~36,819 · see page 3
6,352
Hypertension register
+9.42% in 3 yrs · England +5.60%
777
SMI register
8.2% of Manchester (LAD)'s
1,360
COPD register
Reviews +3.38% in 3 yrs
Forecast to 2030
7,856
Hypertension patients, 2030
+1,504 on today
81.9%
QRISK ≥20% on statins, 2030
+6.80pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews leave 832 patients unreviewed.
Across 2,453 asthma patients, 66.1% had a review (Manchester (LAD) 67.0%), while prescribing is 2,201 rate per 1,000 aged 5-19 (England 1,488 rate).
Pre-school MMR2 and booster coverage trail targets.
Age-5 coverage is 75.3% for MMR2 (13.7 pp below MMR1 at 89.0%) and 69.9% for the 4-in-1 booster, below the 95.0% target.
Breast screening growth outpaces England.
Three-year breast screening coverage rose +32.6% (England +8.4%), though current coverage at 61.2% still trails England (69.9%) and the ICB (68.8%).
Population, age and ethnicity
Children comprise 24.3% of registered patients, alongside an 18.0% Black resident population
Across 46,051 registered patients, children aged 0-17 represent 24.3% (11,170 patients), exceeding Manchester (LAD) (21.4%), NHS Greater Manchester Integrated Care Board (21.8%), and England (19.6%). Patients aged 65+ form 13.2% (6,058 patients), above Manchester (LAD) (9.6%) but below the ICB (14.9%) and England (17.9%). Local Census usual residents include 18.0% Black, African, Caribbean, or Black British (LAD 11.9%, ICB 4.7%, England 4.2%) and 8.8% Asian (LAD 20.9%, ICB 13.6%, England 9.6%). These figures reflect resident Census geography rather than confirmed registered-patient ethnicity.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 54.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 77.6% across the registered PCN population
Core20 cohort (IMD quintile 1) comprises 77.6% of registered patients at PCN level, exceeding Manchester (LAD) (59.8%), NHS Greater Manchester Integrated Care Board (40.7%), and England (21.0%).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
777
SMI register
1.68% recorded prevalence
453
Learning disability register
0.98% recorded prevalence
18
Care homes, 601 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
Recorded severe mental illness prevalence is 1.7% (777 patients) and learning disability is 1.0% (453 patients), exceeding Manchester (LAD) (1.3% and 0.7%), NHS Greater Manchester Integrated Care Board (1.1% and 0.6%), and England (1.0% and 0.6%). The PCN catchment contains 18 care homes with 601 beds, though capacity does not establish registered resident numbers. Higher recorded prevalence may reflect local morbidity patterns or proactive diagnosis, testable by clinical register audit.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.7% (England 1.0%). Recorded blood pressure checks match England at 83.4%. Annual BMI checks reach 79.1% (England 82.1%), rising +0.6 pp over 2023 to 2025 (England +5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,352
Hypertension register
+9.42%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+3.23pp
BP control, under 80
≤140/90 · −1.08pp aged 80+
+1,504
More patients by 2030
Forecast 7,856 (16.43%)
Hypertension case-finding and control
Hypertension prevalence is 13.7% (6,352 patients), below England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%) but above Manchester (LAD) (10.5%). Recent blood pressure monitoring reached 90.0% (England 90.0%). Overall treatment to target was 70.8% (England 70.3%, NHS Greater Manchester Integrated Care Board 71.4%). Blood pressure control in patients aged under 80 was 68.9% (England 67.8%). However, control for patients aged 80 and over was 80.6% (England 81.2%), falling 1.3% over 2023 to 2025 while England rose +2.2% and NHS Greater Manchester Integrated Care Board rose +2.7%. Lagging blood pressure control among older patients could reflect adherence or recall gaps, which practice audits could test.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 65.9%, above England (63.6%) but below Manchester (LAD) (70.5%). Statin coverage in diabetes without CVD is 75.3%, above England (73.2%) and below Manchester (LAD) (79.8%). Lower uptake than the borough could reflect prescribing variation, which practice audits could test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 88,871 | £1.80 | £1.94 | £1.86 | £159,968 |
| Cardiovascular (all), 2025 | 124,088 | £2.42 | £3.15 | £3.33 | £300,293 |
In 2026, the PCN prescribed 88,871 lipid-regulating items at £1.80 per item, below Manchester (LAD) (£2.21), NHS Greater Manchester Integrated Care Board (£1.94), and England (£1.86). This represents £5,332 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.74%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.05%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 5.7% (England 6.6%, Manchester (LAD) 5.8%), while asthma management prescribing reaches 2,201 rate per 1,000 aged 5-19 (England 1,488 rate). With a 66.1% review rate (Manchester (LAD) 67.0%), an estimated 832 asthma patients remain unreviewed across 2,453 registered. COPD prevalence is 2.9% (England 1.9%), rising +14.6% over 2023 to 2025 (England +2.6%), with 75.3% reviewed (England 76.4%). Elevated paediatric prescribing could reflect acute reliever reliance, which prescribing audits could test.
Cancer register and children's immunisation
Cancer prevalence is 3.0% (1,364 patients), below England (3.8%) and above Manchester (LAD) (2.2%). In Q1 2025/26, 6-in-1 coverage at 24 months reached 92.0% (England 92.2%). At age 5, MMR dose 2 coverage was 75.3% (England 82.8%), trailing MMR dose 1 (89.0%) by 13.7 pp. The 4-in-1 booster reached 69.9% (England 80.9%), below the 95.0% target by 25.1 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage in NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 cases), in line with England (55.3%) but below the 75.0% national ambition by 2028 by 19.4 pp. Staged cases represented 70.8% of all 16,492 registered cancers (England 67.0%). Closing this gap requires an estimated 2,268.2 additional early-stage diagnoses annually across the ICB. At PCN level, cervical screening coverage in women aged 25 to 49 is 61.1%, trailing England (66.8%) and the ICB (65.9%), although above Manchester (LAD) (57.2%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the 62-day cancer referral to treatment standard (385 of 528.5 pathways), below the 85.0% standard by 12.2 pp. This trailed Northern Care Alliance NHS Foundation Trust (78.6%), Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%), and NHS Greater Manchester Integrated Care Board (75.7%), but exceeded England (71.2%). On the 28-day faster diagnosis standard, the trust reached 80.1% (4,706 of 5,878 pathways), exceeding the 75.0% standard by 5.1 pp, ahead of the ICB (79.5%) and England (79.3%), though behind Tameside and Glossop (82.5%).
| Pathways within standard (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 0.00 | 21.40 |
| CT | 14.66 | 4.10 | 0.18 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 0.00 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 1.51 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.45 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 0.80 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In June 2026 (provisional), community health service contacts for Manchester borough residents totaled 96,995 across all ages. Adults aged 65 and over accounted for 42,015 of these contacts, representing 43.3% of all community service activity for borough residents. These figures describe local authority resident activity rather than PCN-level activity.
Practice variation and patient experience
Phone access spans 27.1 pp and good experience spans 19.8 pp across practices
In 2025/26, overall QOF achievement ranged from 75.6% at Newton Heath Medical Centre to 92.7% at Simpson Medical Practice (England 92.5%). Vaccination and immunisation achievement spanned 27.0 pp across captured practices, from 15.6% at Mp Victoria Mill to 42.7% at Simpson Medical Practice (England 55.2%). Hazeldene Medical Centre achieved 99.0% on the clinical domain.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Hazeldene | 72 | 38.6 | 89.3% | 87.7% | 91.8% |
| Mp Victoria Mill | 109 | 100.0 | 76.5% | 80.3% | 91.5% |
| Whitley Road | 117 | 93.2 | 74.1% | 75.6% | 86.4% |
| Simpson Medical | 101 | 87.8 | 62.2% | 75.3% | 82.2% |
| St George's | 93 | 81.3 | 70.5% | 69.4% | 81.3% |
| Newton Heath | 90 | 89.4 | 78.9% | 73.6% | 80.5% |
| Droylsden Rd | 110 | 94.6 | 62.7% | 83.2% | 72.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eight clinical measures trail England over three years, while three areas outpace national growth
Three-year trajectories trail England across 8 measures. Learning disability prevalence fell 2.5% over three years (England +5.4%), while severe mental illness annual BMI recording rose +0.6 pp (England +5.1 pp), leaving coverage at 79.1% (England 82.1%). Blood pressure control for patients aged 80+ fell 1.3% (England +2.2%), and smoking cessation offers fell 2.2 pp (England +0.1 pp). Conversely, 3-year growth outpaced England in breast screening (+32.6% vs +8.4%), asthma reviews (+9.7% vs +4.4%), and high-risk lipid therapy (+11.5% vs +6.2%). Slower physical health checks may reflect annual recall bottlenecks, testable by practice audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
BMI record (SMI)
BP control, 80+
Heart failure reviews
Alcohol record (psychosis)
Breast screening (53-70)
Asthma reviews
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (601 beds) | n/a | Schools (catchment) | 63 | n/a |
| Children's centres | 4 | 34 | Places of worship | 41 | 289 |
| Libraries | 2 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 13 | 68 | Primary academies | 8 | 50 |
| Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Asthma reviews cover 66.1% of 2,453 register patients (Manchester (LAD) 67.0%, England 65.7%), leaving 832 patients without a recorded 12-month review. For discussion: run a single-template asthma recall combining annual review with inhaler prescribing checks, offering after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR2 and booster catch-up
In Q1 2025/26, age-5 MMR2 is 75.3% (England 82.8%), 13.7 pp below MMR1 (89.0%), and 4-in-1 is 69.9% (England 80.9%), 25.1 pp below the 95.0% target. For discussion: audit age-5 cohorts missing MMR2 or 4-in-1 boosters and test flexible catch-up clinics. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Hypertension case-finding and older-patient recall
Recorded hypertension is 13.7% (6,352 of 46,051 patients; Manchester (LAD) 10.5%, England 15.2%), a modelled gap of -1,511 to +661 patients; 80+ BP control fell 1.3% (England +2.2%). For discussion: search records for uncoded raised BP readings and run structured recall for patients aged 80+ above target. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric appointment capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Core20 targeted outreach review (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall review (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older hypertension recall review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage capacity review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR2 and booster catch-up (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Hypertension case-finding and older-patient recall (p12) | Hypertension register · Hypertension: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
